Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology

Journal of Clinical Microbiology

Volumn 47, Issue 8, 2009, Pages 2544-2550

  Ntziora, F ^a   Paraskevis, D ^a   Haida, C ^a   Magiorkinis, E ^a   Manesis, E ^b   Papatheodoridis, G ^c   Manolakopoulos, S ^c   Beloukas, A ^a   Chryssoy, S ^a   Magiorkinis, G ^a   Sypsa, V ^a   Hatzakis, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Liver Unit   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; LAMIVUDINE; VIRUS DNA;

ARTICLE; CODON; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DNA SEQUENCE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; M204V GENE; MAJOR CLINICAL STUDY; MOLECULAR BEACON; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; VIRUS DETECTION; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 68549125143     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00045-09     Document Type: Article

References (34)

1. Aberle, S. W., J. Kletzmayr, B. Watschinger, B. Schmied, N. Vetter, and E. Puchhammer-Stöckl. 2001. Comparison of sequence analysis and the INNOLiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J. Clin. Microbiol. 39:1972-1974.
2. Ahmadian, A., M. Ehn, and S. Hober. 2006. Pyrosequencing: history, biochemistry and future. Clin. Chim. Acta 363:83-94.
3. Allen, M. I., J. Gauthier, M. DesLauriers, E. J. Bourne, K. M. Carrick, F. Baldanti, L. L. Ross, M. W. Lutz, and L. D. Condreay. 1999. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 37:3338-3347.
4. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
5. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
6. Bai, Y. J., J. R. Zhao, G. T. Lv, W. H. Zhang, Y. Wang, and X. J. Yan. 2003. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J. Gastroenterol. 9:2344-2347.
7. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
8. Delaney, W. E., IV, H. Yang, C. E. Westland, K. Das, E. Arnold, C. S. Gibbs, M. D. Miller, and S. Xiong. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77:11833-11841.
9. Hussain, M., C. J. Chu, E. Sablon, and A. S. Lok. 2003. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J. Clin. Microbiol. 41:3699-3705.
10. Hussain, M., S. Fung, E. Libbrecht, E. Sablon, C. Cursaro, P. Andreone, and A. S. Lok. 2006. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 44:1094-1097.
11. Kim, J. W., H. S. Lee, G. H. Woo, J. H. Yoon, J. J. Jang, J. G. Chi, and C. Y. Kim. 2001. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after longterm lamivudine therapy. Clin. Infect. Dis. 33:403-405.
12. Kirishima, T., T. Okanoue, Y. Daimon, Y. Itoh, H. Nakamura, A. Morita, T. Toyama, and M. Minami. 2002. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol. 37:259-265.
13. Kumar, S., K. Tamura, and M. Nei. 2004. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinformatics 5:150-163.
14. Liaw, Y. F. 2001. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir. Chem. Chemother. 12(Suppl. 1):67-71.
15. Liaw, Y. F., R. N. Chien, C. T. Yeh, S. L. Tsai, and C. M. Chu. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
16. Locarnini, S., A. Hatzakis, J. Heathcote, E. B. Keeffe, T. J. Liang, D. Mutimer, J. M. Pawlotsky, and F. Zoulim. 2004. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 9:679-693.
17. Lok, A. S., C. L. Lai, N. Leung, G. B. Yao, Z. Y. Cui, E. R. Schiff, J. L. Dienstag, E. J. Heathcote, N. R. Little, D. A. Griffiths, S. D. Gardner, and M. Castiglia. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
18. Lok, A. S., F. Zoulim, S. Locarnini, A. Mangia, G. Niro, H. Decraemer, G. Maertens, F. Hulstaert, K. De Vreese, and E. Sablon. 2002. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40:3729-3734.
19. Nainan, O. V., M. L. Khristova, K. Byun, G. Xia, P. E. Taylor, C. E. Stevens, and H. S. Margolis. 2002. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J. Med. Virol. 68:319-327.
20. Newton, C. R., A. Graham, L. E. Heptinstall, S. J. Powell, C. Summers, N. Kalsheker, J. C. Smith, and A. F. Markham. 1989. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17:2503-2516.
21. Ono-Nita, S. K., N. Kato, Y. Shiratori, T. Masaki, K. H. Lan, F. J. Carrilho, and M. Omata. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
22. Osiowy, C., and E. Giles. 2003. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J. Clin. Microbiol. 41:5473-5477.
23. Papatheodoridis, G. V., E. Dimou, K. Dimakopoulos, S. Manolakopoulos, I. Rapti, G. Kitis, D. Tzourmakliotis, E. Manesis, and S. J. Hadziyannis. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42:121-129.
24. Papatheodoridis, G. V., E. Dimou, and V. Papadimitropoulos. 2002. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. J. Gastroenterol. 97:1618-1628.
25. Papatheodoridis, G. V., S. Manolakopoulos, G. Dusheiko, and A. J. Archimandritis. 2008. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis. 8:167-178.
26. Pas, S. D., R. A. de Man, E. Fries, A. D. Osterhaus, and H. G. Niesters. 2002. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J. Clin. Virol. 25:63-71.
27. Piatek, A. S., S. Tyagi, A. C. Pol, A. Telenti, L. P. Miller, F. R. Kramer, and D. Alland. 1998. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat. Biotechnol. 16:359-363.
28. Punia, P., P. Cane, C. G. Teo, and N. Saunders. 2004. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J. Hepatol. 40:986-992.
29. Sokol, D. L., X. Zhang, P. Lu, and A. M. Gewirtz. 1998. Real time detection of DNA · RNA hybridization in living cells. Proc. Natl. Acad. Sci. USA 95:11538-11543.
30. Stuyver, L. J., S. A. Locarnini, A. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
31. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
32. Tyagi, S. 1996. Taking DNA probes into a protein world. Nat. Biotechnol. 14:947-948.
33. Wang, J. H., S. N. Lu, C. M. Lee, J. F. Lee, and Y. P. Chou. 2002. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand. J. Gastroenterol. 37:366-369.
34. Yang, D. H., W. F. Liang, Y. J. Xie, N. F. Zhao, and J. Fan. 2002. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine. Hepatobiliary Pancreat. Dis. Int. 1:232-237.